Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Xiaoning Wu;Jialing Zhou;Wen Xie;Huiguo Ding;Xiaojuan Ou;Guofeng Chen;Anlin Ma;Xiaoyuan Xu;Hui Ma;Youqing Xu;Xiaoqing Liu;Tongtong Meng;Lin Wang;Yameng Sun;Bingqiong Wang;Yuanyuan Kong;Hong Ma;Hong You;Jidong Jia;
Infection and drug resistance 2019 Vol. 12 pp. 745--757
264
wu2019entecavirinfection

Abstract

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Access

DOI:
10.2147/IDR.S185120
URL:
https://www.dovepress.com/getfile.php?file

Citation

ID: 8066
Ref Key: wu2019entecavirinfection
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
8066
Unique Identifier:
10.2147/IDR.S185120
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store